Revolutionizing BPH Treatment: Zenflow Raises $24 Million in Series C Funding

Zenflow, Inc., a pioneering medical technology company dedicated to transforming the treatment of benign prostatic hyperplasia (BPH), has successfully raised $24 million in funding. This significant investment underscores the urgent need for innovative solutions addressing the plight of the 40 million men in the United States and over 500 million globally who suffer from urinary obstruction related to BPH. Despite the availability of medications, many patients experience inadequate relief and are hesitant to pursue invasive surgical options that carry risks of troublesome side effects, including sexual dysfunction. In response to this pressing clinical demand, Zenflow has developed the groundbreaking Spring System, a revolutionary device designed to provide effective and lasting relief in a simple, atraumatic procedure that can be performed directly in a urologist's office. The funding will be pivotal in advancing clinical trials, scaling up production, and enhancing market outreach, allowing more patients to access this much-needed alternative to traditional treatments. With ongoing clinical trials yielding promising results extending up to four years post-treatment, Zenflow is poised to redefine the standard of care for men suffering from BPH. This funding not only highlights the confidence investors have in Zenflow's vision and technology but also signifies a commitment to improving the quality of life for millions facing debilitating urinary obstruction.